GlobeNewswire

Merus Announces IND Clearance for MCLA-145

Del

MCLA-145 is a full-length human bispecific antibody binding to PD-L1 and CD137

UTRECHT, The Netherlands, Jan. 07, 2019 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS), a clinical-stage immuno-oncology company developing Biclonics®, innovative full-length human bispecific antibody therapeutics, today announced the U.S. Food and Drug Administration (FDA) has accepted the Investigational New Drug (IND) application for MCLA-145, a first-in-class PD-L1 x CD137 Biclonics® being developed in collaboration with Incyte (Nasdaq: INCY), for the treatment of solid tumors. 

“We are pleased to announce the IND authorization to proceed from the FDA and to disclose more details around our latest Biclonics® program today,” said Andres Sirulnik, M.D., Ph. D., Executive Vice President and Chief Medical Officer of Merus. “Our preclinical work has demonstrated that MCLA-145 has the potential to overcome the known side effects of CD137 agonists currently in development and to address a significant unmet need in patient populations not benefitting from current immunotherapeutic agents. We expect to initiate the clinical trial program for MCLA-145 during the second quarter of 2019 and we look forward to continuing our collaboration with Incyte on MCLA-145’s global development.”          

Discovered through an unbiased functional screening of multiple immunomodulatory target combinations, MCLA-145 is a Biclonics® T-cell agonist that binds with high affinity and specificity to human PD-L1 and CD137 in preclinical models. The unique immunostimulatory profile of MCLA-145 derives from the ability to potently activate immune effector cells in the context of the tumor microenvironment while simultaneously blocking inhibitory signals in the same immune cell population.

Merus is developing MCLA-145 as part of a collaboration entered into with Incyte in December 2016 to potentially develop and commercialize up to 11 bispecific and monospecific antibodies from the Merus Biclonics® platform. Under the terms of the collaboration, Merus will retain all rights to develop and commercialize MCLA-145, if approved, in the United States, while Incyte has rights to develop and commercialize MCLA-145, if approved, outside the United States.

About Merus N.V.

Merus is a clinical-stage immuno-oncology company developing innovative full-length human bispecific antibody therapeutics, referred to as Biclonics®. Biclonics, which are based on the full-length IgG format, are manufactured using industry standard processes and have been observed in preclinical and clinical studies to have several of the same features of conventional human monoclonal antibodies, such as long half-life and low immunogenicity. For additional information, please visit Merus’ website, www.merus.nl.

Forward Looking Statement

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including without limitation statements regarding the characteristics and immunostimulatory profile of MCLA-145; the potential for MCLA-145 to overcome known side effects of CD137 agonists currently in development and to address a significant unmet need in patient populations not benefitting from current immunotherapeutic agents; the commencement and timing of the clinical trial program for MCLA-145; the continuing collaboration with Incyte on MCLA-145’s global development, and potential to develop and commercialize up to 11 bispecifc and monospecific antibodies from the Merus Biclonics® platform; and whether any of the programs under the collaboration will be successful, including for MCLA-145. .

These forward-looking statements are based on management’s current expectations. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including, but not limited to, the following: our need for additional funding, which may not be available and which may require us to restrict our operations or require us to relinquish rights to our technologies or Biclonics® and bispecific antibody candidates; potential delays in regulatory approval, which would impact our ability to commercialize our product candidates and affect our ability to generate revenue; the lengthy and expensive process of clinical drug development, which has an uncertain outcome; the unpredictable nature of our early stage development efforts for marketable drugs; potential delays in enrollment of patients, which could affect the receipt of necessary regulatory approvals; our reliance on third parties to conduct our clinical trials and the potential for those third parties to not perform satisfactorily; we may not identify suitable Biclonics® or bispecific antibody candidates under our collaboration with Incyte or Incyte may fail to perform adequately under our collaboration; our reliance on third parties to manufacture our product candidates, which may delay, prevent or impair our development and commercialization efforts; protection of our proprietary technology; our patents may be found invalid, unenforceable, circumvented by competitors and our patent applications may be found not to comply with the rules and regulations of patentability; we may fail to prevail in potential lawsuits for infringement of third-party intellectual property; and our registered or unregistered trademarks or trade names may be challenged, infringed, circumvented or declared generic or determined to be infringing on other marks.

These and other important factors discussed under the caption “Risk Factors” in our Annual Report on Form 20-F filed with the Securities and Exchange Commission, or SEC, on April 28, 2017, and our other reports filed with the SEC, could cause actual results to differ materially from those indicated by the forward-looking statements made in this press release. Any such forward-looking statements represent management’s estimates as of the date of this press release. While we may elect to update such forward-looking statements at some point in the future, we disclaim any obligation to do so, even if subsequent events cause our views to change, except as required under applicable law. These forward-looking statements should not be relied upon as representing our views as of any date subsequent to the date of this press release.

Investor and Media Inquiries:

Merus:

Jillian Connell
Merus N.V.
617-955-4716
j.connell@merus.nl

Om GlobeNewswire

GlobeNewswire
GlobeNewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://globenewswire.com

GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Følg saker fra GlobeNewswire

Registrer deg med din epostadresse under for å få de nyeste sakene fra GlobeNewswire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra GlobeNewswire

Elemica Wins Three Prestigious Supply Chain Awards This Month25.6.2019 17:03:00 CESTPressemelding

Elemica Awarded for Creating Supply Chain Excellence With Next-Gen Technologies ATLANTA, June 25, 2019 (GLOBE NEWSWIRE) -- Elemica, the leading Digital Supply Network for process manufacturing industries, announces that the company has been honored with two top supply chain awards, and Gary Neights, Senior Director of Product Management at Elemica, was named a Top 50 Tech Visionary. “The industry is recognizing Elemica and its people for their innovative solutions and robust platform that produces exceptional business results for clients,” said David Cahn, Director of Global Marketing at Elemica. “Elemica has been instrumental this year in helping numerous global businesses move forward on their digital transformations, resulting in improved visibility, greater efficiencies, and better bottom line results.” Supply & Demand Chain Executive has selected Elemica as a recipient of the SDCE 100 Award for the 7th consecutive year. Food Logistics magazine has bestowed Elemica with a Top Green

cPacket Networks to Offer Cloud Visibility Service with Amazon Virtual Private Cloud Traffic Mirroring25.6.2019 17:00:00 CESTPressemelding

New cCloud Solution Provides Customers Access to Network-Level Packet Data for Performance and Security Monitoring SAN JOSE, Calif., June 25, 2019 (GLOBE NEWSWIRE) -- cPacket Networks, a leading provider of next-generation network performance/security monitoring and packet brokering solutions, has launched the cCloud cloud-based network visibility-as-a-service (VaaS) offering by working with Amazon Web Services (AWS) and leveraging the traffic mirroring feature offered by Amazon Virtual Private Cloud (Amazon VPC). “While many of our customers are migrating workloads to the cloud, until now it happened to be a black-box for them, from a performance and security perspective. The cPacket solution builds on Amazon Virtual Private Cloud (Amazon VPC) traffic mirroring to remove blind spots, provide complete visibility, and make the cloud transition smooth for our customers,” said Brendan O’Flaherty, CEO of cPacket Networks. Without the rich insights of packet data, full visibility is comprom

PowerPlan Expands Leadership Team To Support Continued Company Growth25.6.2019 16:42:00 CESTPressemelding

ATLANTA, June 25, 2019 (GLOBE NEWSWIRE) -- PowerPlan, Inc., a leading provider of strategic corporate performance management for asset-intensive companies, announced today the appointment of Brett Bertz as its Chief Customer Officer and John Budala as its Chief Information Officer. These two positions, new to PowerPlan, will help the company sustain growth in the areas of customer success and technological infrastructure. Bertz and Budala report directly to the company’s CEO, Joe Gomes. “As PowerPlan continues to evolve to meet the needs of our customers, we are thrilled to have Brett and John join our leadership team,” said Gomes. “Brett and John have invaluable experience and have proven to lead through innovation.” Both Bertz and Budala join PowerPlan with extensive experience meeting and exceeding the needs of their customers, and building strong, progressive relationships with industry partners and their internal teams. Bertz has a history of building customer-centric cultures. He

NEP Group Acquires HDR, Expanding Its Broadcast and Media Solutions Capabilities in Europe and Worldwide25.6.2019 16:22:00 CESTPressemelding

PITTSBURGH, Pa. USA, June 25, 2019 (GLOBE NEWSWIRE) -- NEP Group, the leading worldwide outsourced technical production partner supporting premier content producers of live sports and entertainment, announced that it has signed a definitive agreement to purchase HDR Group, a full-service production partner headquartered in Stockholm, Sweden. The agreement became effective on June 17, 2019, and the deal is expected to close in early Q3 or Q4 of this year, conditional upon the approval of the Swedish Competition Authority. Prior to closing, NEP and HDR will continue to operate as separate and independent companies. HDR was founded in 2007 and today employs more than 100 employees who support clients in the live sports, entertainment and broadcast markets in Sweden, Norway, Denmark and Finland. The addition of HDR is consistent with NEP’s stated strategy to become the world leader in Broadcast Services and Media Solutions and increases NEP’s ability to serve its clients in the Nordic regi

Kim Crawford Wines Partners With US Open Tennis Championships25.6.2019 16:00:00 CESTPressemelding

No. 1-Selling Sauvignon Blanc in U.S. Becomes the Official Wine of the US Open Tennis Championships in New, Multi-Year Agreement WHITE PLAINS, N.Y. and MARLBOROUGH, New Zealand, June 25, 2019 (GLOBE NEWSWIRE) -- The United States Tennis Association (USTA) and Kim Crawford Wines today announced a new partnership that names Kim Crawford Wines as the official wine of the US Open Tennis Championships. The new, multi-year agreement commences with the 2019 Open. The No. 1-selling Sauvignon Blanci and leading New Zealand wine brandii in the U.S., Kim Crawford Wines will #ServeUpKim to US Open fans with a permanent brand presence on the grounds of the USTA Billie Jean King National Tennis Center. Kim Crawford will further support the partnership at retail locations across the country with impactful displays and an exciting sweepstakes, in which the winner will receive an all-expenses paid VIP experience at the 2020 US Open. The sweepstakes begins July 1 and ends August 31, during which consume

Appian Announces Winners of its Annual Hackathon at Appian World25.6.2019 15:00:00 CESTPressemelding

RESTON, Va., June 25, 2019 (GLOBE NEWSWIRE) -- Appian (NASDAQ: APPN) congratulates the winners of the Appian World 2019 Hackathon. Participants were tasked with leveraging the Appian platform to showcase the effectiveness and speed of low-code development. Hundreds of registrations were narrowed down to three winners by a seasoned panel of judges including Black Girls Code Founder and CEO, Kimberly Bryant and Neil Ward-Dutton, IDC’s VP of AI and DX European Research Practices and Appian executives. Finalists attended Appian World 2019 in San Diego, CA where they showcased their solutions to the all-star panel of judges. The judges based their decisions on the originality of the idea underlying the application, how well that idea was executed by the developer, and the beneficial impact of the solution. The submissions, covering a variety of industries and use cases, all exemplified the power and simplicity of building enterprise applications on the Appian platform. The 2019 winners are: